ArticleJNCI cancer spectrum2025
Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy.
Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patterns and predictors of cognitive function and post-traumatic growth in cancer patients: a latent profile analysis.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCancer-related cognitive impairment is a significant concern, yet data assessing long-term changes from pretreatment baselines are limited.
methodsIn this large nationwide study, patients with breast cancer and lymphoma and controls were assessed at pre-chemotherapy, post-chemotherapy, 6-month, 1-year, and 2-year follow-ups. Cognitive function was measured using self-reported and performance-based assessments. The analysis included 225 participants: breast cancer (41 patients/36 controls) and lymphoma (73 patients/75 controls). Cognitive trajectories were estimated using longitudinal linear mixed models, adjusting for demographic, clinical, and psychosocial factors. A minimal clinically important difference cutoff identified changes over time in perceived cognitive impairment.
resultsPatients with breast cancer reported greater cognitive complaints than controls, with declines in FACT-Cog Total (β = -17.17, P < .001), Perceived Cognitive Impairment (β = -11.09, P < .001), and Perceived Cognitive Abilities (β = -3.60, P = .03) from pre-chemotherapy to 2-year follow-up. Declines were observed in memory (Rey Auditory Verbal Learning Test [RAVLT] Immediate Recall: β = -1.53, P = .04) and executive function (phone fluency: β = -1.53, P = .02) at 1 year. Patients with lymphoma also showed more complaints, with declines in Perceived Cognitive Impairment (β = -6.19, P = .01), poorer RAVLT Immediate (β = -1.62, P < .001), Delayed Recall (β = -1.72, P < .001), and phone fluency (β = -2.46, P < .001) from pre-chemotherapy to 1-year follow-up.
conclusionCompared with controls, patients with breast cancer and lymphoma showed persistent cognitive worsening up to 1-year posttreatment, and patients with breast cancer reported perceived impairment at 2 years compared with controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.